Table 2.
Quality assessment of included studies.
| Year | Study | Study design | Sample Size | Inclusion and exclusion | Randomization | Statistic | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | Experiment unit | No. | Calculation | Criteria | Exclusion | No. | Randomization | Confounder | Blinding | Outcome measure | Methods, software | Assumption | ||||
| 2017 | Chen26 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| 2021 | Liang27 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| 2020 | Song32 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ||
| 2018 | Li20 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| 2020 | Wang28 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | ||
| 2019 | Liu31 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| 2018 | Ouyang19 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ||
| 2022 | Liang29 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | ||
| 2018 | Zhu30 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| 2020 | Yang33 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| 2019 | Ouyang34 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | ||
| Year | Study | Animals | Procedures | Results | ICP/MAP | Cell | Exosome | |||||||||
| Species | Further | What | When | Where | Why | Summary | Nommalization by MAP | Images of traces | APO test a | Phenotype b | Label | Morphology | Structural changes | Score | ||
| 2017 | Chen26 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 20 |
| 2021 | Liang27 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 20 |
| 2020 | Song32 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 20 |
| 2018 | Li20 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 18 |
| 2020 | Wang28 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 15 |
| 2019 | Liu31 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 18 |
| 2018 | Ouyang19 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 18 |
| 2021 | Liang29 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 13 |
| 2018 | Zhu30 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 17 |
| 2020 | Yang33 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 19 |
| 2019 | Ouyang34 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 21 |
Abbreviation: ICP/MAP, intracavernous pressure/mean artery pressure.
aApomorphine test to verify erectile dysfunction before administration of exosomes.
bStem cell phenotype identification.